Daily Cosmetic Research Analysis

IMPORTANCE: Multiple botulinum toxin A formulations were approved by the US Food and Drug Administration for treating the glabellar rhytids. A comparative quantitative evaluation of their effects on the glabella has not been conducted. OBJECTIVE: To provide an objective quantitative assessment of the effect of 4 botulinum toxin A formulations on glabellar strain across using dynamic 3-dimensional photogrammetry. DESIGN, SETTING, AND PARTICIPANTS: This single-center, double-blind clinical trial, conducted at the University of Pennsylvania Division of Plastic Surgery clinic, randomized 143 female individuals aged 30 to 65 years into 4 arms recei

BACKGROUND: With the increasing demand for minimally invasive aesthetic procedures, intradermal injection has emerged as a promising method to improve skin condition. However, there is a lack of robust clinical evidence supporting the efficacy and safety of intradermal collagen injections. OBJECTIVE: The purpose of this study is to investigate the improvement of facial skin and safety of collagen intradermal injections. METHODS: This prospective, multicenter, randomized, assessor-masked clinical trial enrolled 480 subjects aged 18-65 seeking facial skin enhancement. Subjects were randomized into treatment (n = 240) and control (n = 240) groups. The treatment group received three sessions of intradermal collagen injections at four-week intervals. Assessments included the Global Aesthetic Improvement Scale (GAIS), composite scale for skin dryness and dull complexion, Allergan Fine Lines Scale (AFLS), Allergan Skin Roughness Scale (ASRS), skin hydration, elasticity, and safety evaluations. RESULTS: The GAIS and skin improvement rates showed significant differences between groups (P < 0.0001), with the treatment group demonstrating superior efficacy. No significant differences were observed in skin hydration and elasticity (P > 0.05). The treatment group exhibited higher improvement rates in GAIS, dull complexion, fine lines, and skin roughness at 4 weeks post-final injection compared to the control group. No severe treatment-emergent adverse events related to the trial device occurred. CONCLUSION: Intradermal collagen injections significantly enhance skin texture and demonstrate safety and reliability in clinical settings, offering a favorable risk-benefit ratio for appropriate candidates. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

BACKGROUND: Although uterine myomas can be treated with drugs, uterine artery embolization, and high-intensity focused ultrasound, myomectomy is still the most commonly used treatment in women who wish to preserve fertility. This study aimed to assess the current evidence regarding the safety, efficiency, and potential advantages of laparoendoscopic single-site myomectomy (LESS-M) for treating uterine myomas. MATERIALS AND METHODS: We comprehensively searched MEDLINE, Embase, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization's International Clinical Trials Registry Platform from their inception to 16 November 2024. We included Randomized controlled trials and non-randomized studies comparing LESS-M with conventional laparoscopic myomectomy (CLM) for treating uterine myomas. The primary outcomes were perioperative complication rate, postoperative pain, and cosmetic satisfaction. The secondary outcomes included operative time (min), estimated blood loss (ml), hemoglobin drop, blood transfusion, blood transfusion, conversion to laparotomy rate, first exhaust time, postoperative ambulation time, postoperative hospital stay. All analyses were performed using random-effects or fixed-effects models. Exploration of causes of clinical heterogeneity was planned using subgroup analysis and sensitivity analysis. RESULTS: We included 20 studies including 2766 patients in the final analysis. There were no significant differences between LESS-M and CLM in terms of perioperative complication rate (RR, 1.19; 95% CI, 0.65 to 2.18; P = 0.50), postoperative pain scores at 6 h (WMD, -0.25; 95% CI, -0.53 to 0.03; P = 0.08), 24 h (WMD, -0.16; 95% CI, -0.41 to 0.09; P = 0.22), and 48 h (WMD, -0.05; 95% CI, -0.21 to 0.12; P = 0.58). There were also no differences in terms of operative time ( P = 0.56), estimated blood loss ( P = 0.36), hemoglobin drop ( P = 0.77), blood transfusion ( P = 0.87), and first exhaust time ( P = 0.60) between both techniques. LESS-M was associated with higher cosmetic satisfaction ( P < 0.00001), reduction in postoperative pain scores at 1 h ( P = 0.0008) and 12 h ( P = 0.001), shorter postoperative ambulation time ( P = 0.02) and hospital stay ( P = 0.003) comparing with CLM. CONCLUSION: Available evidence suggests that LESS-M may have advantages in some short-term outcomes compared to CLM. However, these findings are primarily based on non-randomized studies, and further high-quality randomized controlled trials are needed to confirm these results.